Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel

Nguyen Dinh Thang, Phan Tuan Nghia, Mayuko Y. Kumasaka, Ichiro Yajima, Masashi Kato

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Vemurafenib has recently been used as drug for treatment of melanomas with BRAFV600E mutation. Unfortunately, treatment with only vemurafenib has not been sufficiently effective, with recurrence after a short period. In this study, three vemurafenib-resistant BRAFV600E melanoma cell lines, A375PR, A375MR and SKMEL-28R, were established from the original A375P, A375M and SKMEL-28 cell lines. Examination of the molecular mechanisms showed that the phosphorylation levels of MEK and ERK, which play key roles in the RAS/RAF/MEK/ERK signaling pathway, were reduced in these three cell lines, with increased phosphorylation levels of pAKTs limited to SKMEL-28R cells. Treatment of SKMEL-28R cells with 100 nM paclitaxel resulted in increased apoptosis and decreased cellular proliferation, invasion and colony formation via reduction of expression levels of EGFR and pAKTs. Moreover, vemurafenib-induced pAKTs in SKMEL-28R were decreased by treatment with an AKT inhibitor, MK-2206. Taken together, our results revealed that resistance mechanisms of BRAFV600E-mutation melanoma cells to vemurafenib depended on the cell type. Our results suggested that paclitaxel should be considered as a drug in combination with vemurafenib to treat melanoma cells.

Original languageEnglish
Pages (from-to)699-705
Number of pages7
JournalAsian Pacific Journal of Cancer Prevention
Volume16
Issue number2
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Keywords

  • AKT
  • BRAFV600E
  • EGFR
  • Melanoma
  • Paclitaxel
  • Treatment resistance
  • Vemurafenib

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel. / Thang, Nguyen Dinh; Nghia, Phan Tuan; Kumasaka, Mayuko Y.; Yajima, Ichiro; Kato, Masashi.

In: Asian Pacific Journal of Cancer Prevention, Vol. 16, No. 2, 01.01.2015, p. 699-705.

Research output: Contribution to journalArticle

Thang, Nguyen Dinh ; Nghia, Phan Tuan ; Kumasaka, Mayuko Y. ; Yajima, Ichiro ; Kato, Masashi. / Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel. In: Asian Pacific Journal of Cancer Prevention. 2015 ; Vol. 16, No. 2. pp. 699-705.
@article{5e1bb543d8f7450b97acc1814b8f3839,
title = "Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel",
abstract = "Vemurafenib has recently been used as drug for treatment of melanomas with BRAFV600E mutation. Unfortunately, treatment with only vemurafenib has not been sufficiently effective, with recurrence after a short period. In this study, three vemurafenib-resistant BRAFV600E melanoma cell lines, A375PR, A375MR and SKMEL-28R, were established from the original A375P, A375M and SKMEL-28 cell lines. Examination of the molecular mechanisms showed that the phosphorylation levels of MEK and ERK, which play key roles in the RAS/RAF/MEK/ERK signaling pathway, were reduced in these three cell lines, with increased phosphorylation levels of pAKTs limited to SKMEL-28R cells. Treatment of SKMEL-28R cells with 100 nM paclitaxel resulted in increased apoptosis and decreased cellular proliferation, invasion and colony formation via reduction of expression levels of EGFR and pAKTs. Moreover, vemurafenib-induced pAKTs in SKMEL-28R were decreased by treatment with an AKT inhibitor, MK-2206. Taken together, our results revealed that resistance mechanisms of BRAFV600E-mutation melanoma cells to vemurafenib depended on the cell type. Our results suggested that paclitaxel should be considered as a drug in combination with vemurafenib to treat melanoma cells.",
keywords = "AKT, BRAFV600E, EGFR, Melanoma, Paclitaxel, Treatment resistance, Vemurafenib",
author = "Thang, {Nguyen Dinh} and Nghia, {Phan Tuan} and Kumasaka, {Mayuko Y.} and Ichiro Yajima and Masashi Kato",
year = "2015",
month = "1",
day = "1",
doi = "10.7314/APJCP.2015.16.2.699",
language = "English",
volume = "16",
pages = "699--705",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "2",

}

TY - JOUR

T1 - Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel

AU - Thang, Nguyen Dinh

AU - Nghia, Phan Tuan

AU - Kumasaka, Mayuko Y.

AU - Yajima, Ichiro

AU - Kato, Masashi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Vemurafenib has recently been used as drug for treatment of melanomas with BRAFV600E mutation. Unfortunately, treatment with only vemurafenib has not been sufficiently effective, with recurrence after a short period. In this study, three vemurafenib-resistant BRAFV600E melanoma cell lines, A375PR, A375MR and SKMEL-28R, were established from the original A375P, A375M and SKMEL-28 cell lines. Examination of the molecular mechanisms showed that the phosphorylation levels of MEK and ERK, which play key roles in the RAS/RAF/MEK/ERK signaling pathway, were reduced in these three cell lines, with increased phosphorylation levels of pAKTs limited to SKMEL-28R cells. Treatment of SKMEL-28R cells with 100 nM paclitaxel resulted in increased apoptosis and decreased cellular proliferation, invasion and colony formation via reduction of expression levels of EGFR and pAKTs. Moreover, vemurafenib-induced pAKTs in SKMEL-28R were decreased by treatment with an AKT inhibitor, MK-2206. Taken together, our results revealed that resistance mechanisms of BRAFV600E-mutation melanoma cells to vemurafenib depended on the cell type. Our results suggested that paclitaxel should be considered as a drug in combination with vemurafenib to treat melanoma cells.

AB - Vemurafenib has recently been used as drug for treatment of melanomas with BRAFV600E mutation. Unfortunately, treatment with only vemurafenib has not been sufficiently effective, with recurrence after a short period. In this study, three vemurafenib-resistant BRAFV600E melanoma cell lines, A375PR, A375MR and SKMEL-28R, were established from the original A375P, A375M and SKMEL-28 cell lines. Examination of the molecular mechanisms showed that the phosphorylation levels of MEK and ERK, which play key roles in the RAS/RAF/MEK/ERK signaling pathway, were reduced in these three cell lines, with increased phosphorylation levels of pAKTs limited to SKMEL-28R cells. Treatment of SKMEL-28R cells with 100 nM paclitaxel resulted in increased apoptosis and decreased cellular proliferation, invasion and colony formation via reduction of expression levels of EGFR and pAKTs. Moreover, vemurafenib-induced pAKTs in SKMEL-28R were decreased by treatment with an AKT inhibitor, MK-2206. Taken together, our results revealed that resistance mechanisms of BRAFV600E-mutation melanoma cells to vemurafenib depended on the cell type. Our results suggested that paclitaxel should be considered as a drug in combination with vemurafenib to treat melanoma cells.

KW - AKT

KW - BRAFV600E

KW - EGFR

KW - Melanoma

KW - Paclitaxel

KW - Treatment resistance

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84925382483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925382483&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2015.16.2.699

DO - 10.7314/APJCP.2015.16.2.699

M3 - Article

VL - 16

SP - 699

EP - 705

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 2

ER -